Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 189 participants.

Also called NCT01229254

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 189 participants (enrolled count) (from the registry)
Sponsor
Portola Pharmaceuticals (from the registry)
Registry
  • NCT NCT01229254
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01229254. Non-randomized; no masking; primary purpose treatment. Start 2010-09 (registry gives no type); primary completion 2010-12 (actual). Results posted on 2017-09-18.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter
Intervention (Drug)
Amiodarone
Intervention (Drug)
Betrixaban 60 mg
Intervention (Drug)
Betrixaban 90 mg
Intervention (Drug)
Betrixaban 30 mg
Lead sponsor
Portola Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01229254
Content hash
da3c0356d2c288940c17644914e833a270608bb32250c91b1aaa8d1003756c5b